Abstract
Serum protein peak at 3,144 m/z is a new biomarker for breast cancer diagnosis and prognosis and showed a higher positive rate than serum CA15-3. Combining 3,144 m/z and CA15-3 testing may improve prognosis of longer survival in breast cancer patients.
Introduction
Recurrence and metastasis remain the primary causes of treatment failure in breast cancer. For patients with node-positive disease—where cancer has already spread to the axillary lymph nodes—accurate prognosis is vital for tailoring follow-up care. The current "gold standard" serum marker, CA15-3, suffers from low sensitivity, often detecting only 15% to 22% of cases. There is a critical clinical need for more sensitive, minimally invasive tools to predict survival outcomes. This study identifies a specific serum protein peak at 3,144 m/z as a potent new biomarker that significantly outperforms CA15-3 in sensitivity and prognostic value for node-positive patients.
Methods
The study utilized Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF MS) to perform proteomic fingerprinting on serum samples from 283 women with node-positive invasive ductal carcinoma. The cohort included various molecular subtypes (Luminal A/B, HER2+, and Triple-negative) and stages (II through IV). Researchers specifically analyzed a protein peak at 3,144 m/z, identified via the TagIdent tool as likely being CD24, a protein known to be involved in cell adhesion and tumor proliferation. Survival data was tracked through June 2011 to calculate 3-year overall survival (OS) rates.
Results
The 3,144 m/z peak demonstrated a positive detection rate of 37.5%, more than triple the 11.4% rate of CA15-3 in the same patient group. Interestingly, the presence of this peak did not strongly correlate with standard clinicopathological metrics like tumor size, TNM stage, or molecular subtype, suggesting it provides independent biological information about tumor aggressiveness. A significant correlation was found with age, as the marker was more frequent in patients over 50 years old (44.7% vs 31.1%, P = 0.019).
Survival analysis showed that patients negative for the 3,144 m/z peak had a significantly better 3-year overall survival rate (89.8%) compared to those who were positive (81.2%, P = 0.045).
The most striking insight was the synergy between markers. Patients who were negative for both CA15-3 and the 3,144 m/z peak had an 89.8% 3-year survival rate. Conversely, those positive for both had a survival rate of only 53.6% (P = 0.011), demonstrating the power of combined testing for identifying high-risk patients.
Cox regression analysis further identified T3–4 stage, lymph node metastasis, and p53 mutation as independent adverse prognostic factors. Protective factors included childbirth (≥2), adjuvant chemotherapy, and radiotherapy.
Discussion
While the 3,144 m/z peak shows promise as a more sensitive indicator than CA15-3, several hurdles remain before clinical implementation. The identity of the peak as CD24 requires definitive confirmation via protein sequencing or specific immunoassays. Furthermore, as a retrospective single-center study, these results need validation in larger, multi-center prospective trials. Future research should also investigate the marker's effectiveness in early-stage (node-negative) breast cancer and the exact biological mechanisms by which this protein fragment influences metastasis.
Summary updated